| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
COH34 analog 1 targets PARG (poly(ADP-ribose) glycohydrolase), an enzyme that hydrolyzes poly(ADP-ribose) (PAR) polymers generated by PARP enzymes during DNA damage repair. As an oxidation analog of COH34, the compound may modulate PARG activity, affecting DNA repair pathways and genomic stability.
|
|---|---|
| ln Vitro |
COH34 analog 1 demonstrates in vitro activity as an oxidation analog of COH34 that can be used to synthesize active compounds. Its utility in studying DNA damage response and genomic stability suggests activity in modulating PARG function and DNA repair pathways.
|
| ln Vivo |
In vivo activity of COH34 analog 1 has been suggested by its potential role in studying DNA damage response and synthetic lethality. The compound supports research into anticancer strategies that exploit vulnerabilities in DNA repair mechanisms, particularly in tumors with repair deficiencies.
|
| Enzyme Assay |
In vitro enzyme assays for COH34 analog 1 involve measuring its effects on PARG activity. The assay typically uses purified PARG enzyme and measures the hydrolysis of poly(ADP-ribose) substrates in the presence of the compound. Inhibition of PARG activity can be quantified, and IC50 values can be determined.
|
| Cell Assay |
In vitro cellular assays for COH34 analog 1 involve treating cancer cell lines with the compound and measuring DNA damage response markers, cell viability, or synthetic lethality. The compound's effects on PARG activity can be assessed by measuring PAR polymer levels in treated cells.
|
| Animal Protocol |
In vivo animal experiments for COH34 analog 1 would typically involve administering the compound to tumor-bearing mouse models to evaluate its effects on DNA damage repair and tumor growth. The compound's potential for studying synthetic lethality in repair-deficient tumors could be assessed in appropriate models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for COH34 analog 1 are limited. The compound has a molecular weight of 325.38 and is soluble in DMSO. Its absorption, distribution, metabolism, and excretion properties have not been fully characterized. Further pharmacokinetic studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicological data for COH34 analog 1 are limited. As a research compound, comprehensive toxicological studies have not been reported. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
COH34 analog 1 (CAS#: 314248-24-3) has the molecular formula C18H15NO3S and a molecular weight of 325.38. Its chemical name is N-((2-hydroxynaphthalen-1-yl)methylene)-4-methylbenzenesulfonamide. The compound is an oxidation analog of the PARG inhibitor COH34.
|
| Molecular Formula |
C18H15NO3S
|
|---|---|
| Molecular Weight |
325.381603479385
|
| Exact Mass |
325.08
|
| CAS # |
314248-24-3
|
| PubChem CID |
135403133
|
| Appearance |
Yellow to orange solid powder
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
517
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C=CC(C)=CC=1)(/N=C/C1=C(C=CC2C=CC=CC1=2)O)(=O)=O
|
| InChi Key |
WCYGPLQLYOSVIH-XDHOZWIPSA-N
|
| InChi Code |
InChI=1S/C18H15NO3S/c1-13-6-9-15(10-7-13)23(21,22)19-12-17-16-5-3-2-4-14(16)8-11-18(17)20/h2-12,20H,1H3/b19-12+
|
| Chemical Name |
(NE)-N-[(2-hydroxynaphthalen-1-yl)methylidene]-4-methylbenzenesulfonamide
|
| Synonyms |
COH34 analog 1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~307.3 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0733 mL | 15.3666 mL | 30.7333 mL | |
| 5 mM | 0.6147 mL | 3.0733 mL | 6.1467 mL | |
| 10 mM | 0.3073 mL | 1.5367 mL | 3.0733 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
